Impact of Race on Efficacy and Safety of Secukinumab Among Patients With Hidradenitis Suppurativa: A Post-Hoc Analysis of the SUNSHINE and SUNRISE Trials
Julia M. Riley,1 Martina Porter,2 Ryan Sullivan,3 Ivette Alarcon,4 Iryna Lobach,4 Christine-Elke Ortmann,4 Angela Llobet Martinez,4 Tiffany Mayo5
Objective
To evaluate the effect of race on the 52-week efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS).
Methods
This post-hoc analysis of pooled data from the phase 3 SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) trials evaluated patients with HS by race (White [n=845], Asian [n=117], Black/African American [n=86], American Indian/Alaska Native [n=24], Native Hawaiian/Pacific Islander [n=1], and multiple [n=10]).
By Week 52, patients received secukinumab per baseline randomization (300 mg every 2 or 4 weeks [SECQ2W or SECQ4W, respectively]) or after switching from placebo at Week 16 (PBO-SECQ2W or PBO-SECQ4W). Efficacy was evaluated at Week 52 using HiSCR50 and other outcome measures as observed; safety was evaluated by the incidence of adverse events.
Results
At Week 52, the proportion of patients achieving HiSCR50 within each treatment group was generally similar, regardless of the race (White [SECQ2W, 62.6%; SECQ4W, 57.4%; PBO-SECQ2W, 51.5%; PBO-SECQ4W, 57.1%]; Asian [SECQ2W, 59.3%; SECQ4W, 56.3%; PBO-SECQ2W, 41.2%; PBO-SECQ4W, 25.0%]; Black/African American [SECQ2W, 57.9%; SECQ4W, 73.7%; PBO-SECQ2W, 80.0%; PBO-SECQ4W, 50.0%]; American Indian/Alaska Native [SECQ2W, 40.0%; SECQ4W, 83.3%; PBO-SECQ2W, 66.7%; PBO-SECQ4W, 80.0%]).
Smaller subgroups (n≤10) were not represented in all treatment arms, although clinical improvements were observed. Variability was attributed to small subgroup sizes. Improvements in other efficacy measures and similar safety profiles were observed across race subgroups at Week 52.
Conclusions
Patients with moderate-to-severe HS who received secukinumab experienced improvements in disease activity and similar safety profiles at Week 52, regardless of race.
Saverio Minervini